Market Movers | Winners: MRNA, PURR, MRVI | Losers: LZB, TMS
A triple-digit gain in a single session dominates a quiet day for the indexes, raising questions about momentum and discipline.
Moderna (MRNA) was the strongest stock of the day, returning +177.0%. The move came against a nearly flat backdrop for the major indexes, with the S&P 500 and the Dow Jones Industrial Average each returning +0.2% while the Nasdaq-100 returned -0.2%. When a single name moves with such force on a quiet tape, the essential question is whether the move is an isolated spike or part of a persistent trend. The day’s biggest winners and losers are below.
Wednesday’s Market Winners
The 8 stocks with the highest returns on the last trading day:
| # | Ticker | Company Name | 1-D Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | MRNA | Moderna | 177.0% | 491.3% |
| 2 | PURR | Hyperliquid Strategies | 30.4% | 163.8% |
| 3 | MRVI | Maravai LifeSciences | 25.8% | 122.2% |
| 4 | TEM | Tempus AI | 24.1% | 3.7% |
| 5 | TWST | Twist Bioscience | 22.6% | 348.9% |
| 6 | SOC | Sable Offshore | 19.8% | -47.0% |
| 7 | DNA | Ginkgo Bioworks | 18.1% | -7.2% |
| 8 | ASTL | Algoma Steel | 17.1% | 16.8% |
Wednesday’s Market Losers
And the 2 stocks with the lowest returns:
| # | Ticker | Company Name | 1-D Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | LZB | La-Z-Boy | -16.9% | -7.8% |
| 2 | TMS | Teamshares | -13.4% | n/a |
Is a triple-digit gain ever more than a one-day story?
In this case, the data shows persistence. Moderna (MRNA) appears on both the one-day and one-month winners lists. Its one-month return is +192.3%, and the move is not isolated to a single session. Excluding today, the stock still gained +5.5% over the other sessions. This performance comes from a company whose market value is about $69.4 billion, even as its revenue declined 27.7% over the last twelve months.
At the other extreme, La-Z-Boy (LZB) was the day’s weakest stock, returning -16.9%. The company’s revenue grew 0.2% over the last twelve months, and it trades at 16.6 times trailing earnings.
Movers Over The Last Week
Widening the window to five trading days, these are the strongest and weakest Market names:
| # | Ticker | Company Name | 1-W Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | MRNA | Moderna | 173.9% | 491.3% |
| 2 | CAPR | Capricor Therapeutics | 90.5% | -72.3% |
| 3 | AMLX | Amylyx Pharmaceuticals | 65.3% | 219.5% |
| 4 | HTFL | HeartFlow | 52.5% | 56.2% |
| 5 | ETON | Eton Pharmaceuticals | 47.9% | 263.6% |
| 6 | WEAV | Weave Communications | 45.9% | -3.7% |
| 7 | AVAH | Aveanna Healthcare | 45.4% | 61.1% |
| 8 | ARX | Accelerant | 43.6% | 19.6% |
| 9 | FDMT | 4D Molecular Therapeutics | 41.2% | 123.5% |
| # | Ticker | Company Name | 1-W Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | EYPT | EyePoint | -53.4% | -65.5% |
| 2 | KLC | KinderCare Learning Companies | -37.3% | -32.6% |
| 3 | BALY | Ballys | -35.5% | -46.5% |
| 4 | FTK | Flotek Industries | -32.3% | 46.1% |
Movers Over The Last Month
And over the last 21 trading days:
| # | Ticker | Company Name | 1-M Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | MRNA | Moderna | 192.3% | 491.3% |
| 2 | AMLX | Amylyx Pharmaceuticals | 108.6% | 219.5% |
| 3 | RCEL | AVITA Medical | 103.1% | 199.7% |
| 4 | ABCL | AbCellera Biologics | 101.2% | 251.2% |
| 5 | OABI | OmniAb | 100.5% | 126.5% |
| # | Ticker | Company Name | 1-M Returns |
YTD Returns |
|---|---|---|---|---|
| 1 | MPLT | MapLight Therapeutics | -67.5% | -30.8% |
| 2 | CAPR | Capricor Therapeutics | -59.7% | -72.3% |
A big move is a starting point, not a conclusion.
The tables earlier in this report are a map of market attention and volatility, not a set of instructions. A disciplined investor uses these lists to identify where risk is being repriced, then begins the real work. The follow-up is always to check the business behind the ticker. A stock’s sudden appearance on a winners or losers list is information, but the decision to act on it requires understanding the fundamentals that will, or will not, support the new price.
The next step is never to trade the list; it is to test it. Our Guidance Momentum screen shows which risers have management raising guidance behind them, and our Buy the Dip screen shows which of the fallers still generate the growth and cash that make a recovery plausible.
Volatility Is The Cost Of Owning Stocks. Concentration Makes It A Bill
Every name on these lists made a move big enough to notice. A diversified holder reads that as noise; a concentrated holder feels it as real money. The difference is not the stock, it is the portfolio around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb bad days, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Let the movers list remind you why diversification exists.